Sales of Shanghai Henlius Biotech’s trastuzumab biosimilar, Hanquyou, in the company’s domestic Mainland China leapt by two-thirds in the first quarter of this year to RMB538.6m ($78m), preliminary figures disclosed by the Chinese firm reveal, as Henlius continues to push ahead with five clinical candidates for the next wave of biosimilars.
Hanquyou is both the first approved trastuzumab biosimilar in China and the first ‘Chinese nationality’ monoclonal antibody biosimilar
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?